The UAB Department of Urology is actively involved in both clinical, basic science, and translational research endeavors. We have a large tissue and biologic fluids library of hundreds of urologic cancer specimens for internal study. This repository is a basis through which we are attempting to identify markers and characteristics to stratify patients into risk groups. We are also investigating renal ischemia in an animal model to identify means of optimizing renal function and markers that predict outcomes.  Our residents spend four-month blocks performing both clinical and basic science research during their tenure at UAB.

The Department of Urology participates in multiple clinical trials. We are members of the Eastern Cooperative Oncology Group and Early Detection Research Network (branch of the National Cancer Institute), actively involved in multi-institutional studies in urologic cancer. Our translational involvement in chemoprevention studies of bladder and prostate cancer is part of the chemoprevention consortium of our NCI Comprehensive Cancer Center. We participate in numerous non-cancer studies including investigating the feasibility of tissue engineering and the role of bladder replacement in both pediatric and neuro-urology patient populations.

We are currently enrolling patients for multiple studies:

  • Predictors of microsurgical varicocele ligation, and mechanisms of male infertility
  • We are part of a nationwide Andrology Research Consortium evaluating etiologies, treatments, and outcomes for male infertility
  • A study combining Bacillus Calmette-Guerin (BCG) with ALT-803, an immunomodulator, in patients undergoing treatment for non-muscle invasive bladder cancer. More information.
  • A phase 3 study to evaluate the efficacy and tolerability of Vicinium in patients with Non Muscle-Invasive Carcinoma in Situ (CIS) and/or High Grade Papillary disease of the bladder previously treated with Bacillus Calmette-Guerin (BCG) More information. 
  • A registry for treatment of upper urinary tract tumors. This project captures information related to the diagnosis of Upper Urinary Tract Tumors, and submitted to a database that is controlled by the Clinical Research Office of the Endourologic Society.
  • The Rare Diseases Clinical Network provides funding for our study on cystinuria patients with kidney stone disease.
  • A phase II trial to assess the safety and effectiveness of Bucillamine on urinary cystine excretion and cystine capacity in patients with cystinuria. More information.
  • A phase III, randomized trial that will assess the efficacy and safety of 600 or 800 units of Dysport injected into the bladder for the treatment of Neurogenic Detrusor Overactivity due to Spinal Cord Injury of Multiple Sclerosis. More information. 

For more information on these studies, including how to enroll, please contact Ralee' Bunt at 205-934-2272, or Lisa Harvey at 205-996-2613.

We also have a state-of-the-art kidney stone laboratory with multiple NIH-funded scientists studying kidney stone disease. Learn more.